Preemptive Analgesia for Primary Dysmenorrhoea

Preemptive Analgesia for Primary Dysmenorrhoea: a Randomized Controlled Trial

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03323671

Enrollment

Registered

2017-10-27

Start date

2017-08-01

Completion date

2017-12-01

Last updated

2017-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhea

Keywords

primary dysmenorrhea, preemptive analgesia

Brief summary

Preemptive analgesia before the release of pain mediators

Detailed description

spasmodic dysmenorrhea is one of the most distressing symptoms in women. adolescents shows a usual absence from school . prostaglandin release is one of the most accepted theory responsible for spasmodic dysmenorrhea. Non steroidal anti inflammatory Drugs were proved to be one of the alternative medications for spasmodic dysmenorrhea. Getting the idea of what is called preemptive anesthesia by blocking the receptors before catching pain mediators the study participants will be divided randomly into 2 group group 1 receiving ttt 2 days before the anticipated menstruation and group 2 receiving ttt only during menstruation as analgesia

Interventions

DRUGpreemptive mefenamic acid

preemptive analgesia before menstrual pain

DRUGmefenamic acid

mefenamic acid given only during menstruation

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

15 Years to 25 Years

Healthy volunteers

Inclusion criteria

* nulliparous ladies * with regular menstrual cycle pattern * those experienced history of dysmenorrhea (primary or spasmodic) * patients able to sallow tables

Exclusion criteria

* irregular cycles * any associated local causes( pelvic infection, endometriosis, fibroid or others) * patients with familial Mediterranean fever or other intermenstrual attacks of abdominal pain * gastric or duodenal ulcers or gastritis * other contraindications to non steroidal anti-inflammatory drugs * patients with severe diminution of vision or color discrimination * patients with any depressive or mood disorders * patients receiving any hormonal treatment

Design outcomes

Primary

Measure	Time frame	Description
change in the Degree of pain	4 months	severity of pain according to visual pain analog scale

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026